Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$10.87 USD
-0.40 (-3.55%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $10.90 +0.03 (0.28%) 7:12 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Cidara Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 36 | 33 | 62 | 43 | 60 |
Receivables | 16 | 6 | 5 | 11 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 7 | 4 | 3 | 0 |
Total Current Assets | 61 | 45 | 72 | 57 | 66 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 2 | 1 |
Total Assets | 67 | 48 | 75 | 60 | 69 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 1 | 1 | 5 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 3 | 7 | 10 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 37 | 13 | 15 | 12 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 25 | 15 | 14 | 14 | 10 |
Total Current Liabilities | 67 | 30 | 34 | 39 | 30 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 4 | 21 | 18 | 11 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 75 | 51 | 54 | 50 | 31 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 433 | 404 | 399 | 345 | 298 |
Retained Earnings | -441 | -407 | -377 | -335 | -260 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -8 | -3 | 22 | 11 | 38 |
Total Liabilities & Shareholder's Equity | 67 | 48 | 75 | 60 | 69 |
Total Common Equity | -8 | -3 | 22 | 11 | 38 |
Shares Outstanding | 4.50 | 3.50 | 3.30 | 2.20 | 1.60 |
Book Value Per Share | -1.82 | -0.83 | 6.54 | 4.87 | 23.65 |
Fiscal Year End for Cidara Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 164 | 29 | 36 | 49 | 50 |
Receivables | 2 | 7 | 16 | 3 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 7 | 6 | 2 | 2 |
Other Current Assets | 2 | 3 | 3 | 4 | 4 |
Total Current Assets | 169 | 47 | 61 | 58 | 62 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 1 | 1 | 1 |
Total Assets | 173 | 53 | 67 | 63 | 68 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 5 | 4 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 36 | 35 | 37 | 16 | 14 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 24 | 25 | 15 | 15 |
Total Current Liabilities | 40 | 65 | 67 | 36 | 31 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 4 | 17 | 18 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 42 | 71 | 75 | 55 | 53 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 674 | 434 | 433 | 432 | 432 |
Retained Earnings | -543 | -452 | -441 | -424 | -416 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 131 | -18 | -8 | 8 | 15 |
Total Liabilities & Shareholder's Equity | 173 | 53 | 67 | 63 | 68 |
Total Common Equity | 131 | -18 | -8 | 8 | 15 |
Shares Outstanding | 7.00 | 4.50 | 4.50 | 4.50 | 4.50 |
Book Value Per Share | 18.71 | -3.95 | -1.82 | 1.79 | 3.42 |